Hoth Therapeutics (HOTH) Competitors

$0.69 +0.05 (+7.81%)

Closing price 04:00 PM Eastern

Extended Trading

$0.67 -0.02 (-3.19%)

As of 07:58 PM Eastern

HOTH vs. OKUR, ZYBT, ELUT, IXHL, and XLO

Should you buy Hoth Therapeutics stock or one of its competitors? MarketBeat compares Hoth Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hoth Therapeutics include OnKure Therapeutics (OKUR), Zhengye Biotechnology (ZYBT), Elutia (ELUT), Incannex Healthcare (IXHL), and Xilio Therapeutics (XLO). These companies are all part of the "pharmaceutical products" industry.

How does Hoth Therapeutics compare to OnKure Therapeutics?

OnKure Therapeutics (NASDAQ:OKUR) and Hoth Therapeutics (NASDAQ:HOTH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

OnKure Therapeutics has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market. Comparatively, Hoth Therapeutics has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market.

OnKure Therapeutics' return on equity of -61.02% beat Hoth Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-61.02%	-55.99%
Hoth Therapeutics	N/A	-165.25%	-143.61%

In the previous week, Hoth Therapeutics had 2 more articles in the media than OnKure Therapeutics. MarketBeat recorded 3 mentions for Hoth Therapeutics and 1 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 0.00 beat Hoth Therapeutics' score of -0.32 indicating that OnKure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OnKure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hoth Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.0% of OnKure Therapeutics shares are held by institutional investors. Comparatively, 7.1% of Hoth Therapeutics shares are held by institutional investors. 2.3% of OnKure Therapeutics shares are held by company insiders. Comparatively, 6.9% of Hoth Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

OnKure Therapeutics is trading at a lower price-to-earnings ratio than Hoth Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A
Hoth Therapeutics	N/A	N/A	-$12.47M	-$0.80	N/A

OnKure Therapeutics presently has a consensus price target of $27.00, suggesting a potential upside of 541.33%. Hoth Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 624.64%. Given Hoth Therapeutics' higher probable upside, analysts clearly believe Hoth Therapeutics is more favorable than OnKure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Hoth Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Hoth Therapeutics beats OnKure Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Hoth Therapeutics compare to Zhengye Biotechnology?

Hoth Therapeutics (NASDAQ:HOTH) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Hoth Therapeutics has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.47, indicating that its share price is 347% less volatile than the broader market.

Zhengye Biotechnology's return on equity of 0.00% beat Hoth Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hoth Therapeutics	N/A	-165.25%	-143.61%
Zhengye Biotechnology	N/A	N/A	N/A

In the previous week, Hoth Therapeutics had 3 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 3 mentions for Hoth Therapeutics and 0 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 0.00 beat Hoth Therapeutics' score of -0.32 indicating that Zhengye Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Hoth Therapeutics	Neutral
Zhengye Biotechnology	Neutral

Hoth Therapeutics currently has a consensus target price of $5.00, suggesting a potential upside of 624.64%. Given Hoth Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Hoth Therapeutics is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hoth Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Zhengye Biotechnology has higher revenue and earnings than Hoth Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hoth Therapeutics	N/A	N/A	-$12.47M	-$0.80	N/A
Zhengye Biotechnology	$16.64M	2.47	-$9.98M	N/A	N/A

7.1% of Hoth Therapeutics shares are owned by institutional investors. 6.9% of Hoth Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Hoth Therapeutics beats Zhengye Biotechnology on 7 of the 12 factors compared between the two stocks.

How does Hoth Therapeutics compare to Elutia?

Elutia (NASDAQ:ELUT) and Hoth Therapeutics (NASDAQ:HOTH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

74.0% of Elutia shares are owned by institutional investors. Comparatively, 7.1% of Hoth Therapeutics shares are owned by institutional investors. 27.6% of Elutia shares are owned by insiders. Comparatively, 6.9% of Hoth Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Elutia has a net margin of 312.09% compared to Hoth Therapeutics' net margin of 0.00%. Elutia's return on equity of 0.00% beat Hoth Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elutia	312.09%	N/A	-53.97%
Hoth Therapeutics	N/A	-165.25%	-143.61%

In the previous week, Hoth Therapeutics had 1 more articles in the media than Elutia. MarketBeat recorded 3 mentions for Hoth Therapeutics and 2 mentions for Elutia. Elutia's average media sentiment score of 0.00 beat Hoth Therapeutics' score of -0.32 indicating that Elutia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elutia	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hoth Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Elutia has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, Hoth Therapeutics has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

Elutia presently has a consensus price target of $6.00, suggesting a potential upside of 417.24%. Hoth Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 624.64%. Given Hoth Therapeutics' higher probable upside, analysts plainly believe Hoth Therapeutics is more favorable than Elutia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Hoth Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Elutia has higher revenue and earnings than Hoth Therapeutics. Hoth Therapeutics is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$12.29M	4.04	$53.38M	$0.86	1.35
Hoth Therapeutics	N/A	N/A	-$12.47M	-$0.80	N/A

Summary

Elutia beats Hoth Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Hoth Therapeutics compare to Incannex Healthcare?

Hoth Therapeutics (NASDAQ:HOTH) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

7.1% of Hoth Therapeutics shares are owned by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are owned by institutional investors. 6.9% of Hoth Therapeutics shares are owned by insiders. Comparatively, 1.3% of Incannex Healthcare shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Hoth Therapeutics has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 7.22, suggesting that its share price is 622% more volatile than the broader market.

In the previous week, Hoth Therapeutics had 3 more articles in the media than Incannex Healthcare. MarketBeat recorded 3 mentions for Hoth Therapeutics and 0 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 3.00 beat Hoth Therapeutics' score of -0.32 indicating that Incannex Healthcare is being referred to more favorably in the news media.

Company	Overall Sentiment
Hoth Therapeutics	Neutral
Incannex Healthcare	Very Positive

Incannex Healthcare's return on equity of -81.01% beat Hoth Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hoth Therapeutics	N/A	-165.25%	-143.61%
Incannex Healthcare	N/A	-81.01%	-76.11%

Hoth Therapeutics has higher earnings, but lower revenue than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than Hoth Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hoth Therapeutics	N/A	N/A	-$12.47M	-$0.80	N/A
Incannex Healthcare	$90K	468.16	-$46.88M	-$1.55	N/A

Hoth Therapeutics currently has a consensus price target of $5.00, indicating a potential upside of 624.64%. Given Hoth Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Hoth Therapeutics is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hoth Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Hoth Therapeutics beats Incannex Healthcare on 9 of the 14 factors compared between the two stocks.

How does Hoth Therapeutics compare to Xilio Therapeutics?

Xilio Therapeutics (NASDAQ:XLO) and Hoth Therapeutics (NASDAQ:HOTH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 7.1% of Hoth Therapeutics shares are owned by institutional investors. 7.5% of Xilio Therapeutics shares are owned by insiders. Comparatively, 6.9% of Hoth Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Xilio Therapeutics presently has a consensus target price of $28.00, indicating a potential upside of 239.39%. Hoth Therapeutics has a consensus target price of $5.00, indicating a potential upside of 624.64%. Given Hoth Therapeutics' higher probable upside, analysts clearly believe Hoth Therapeutics is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Hoth Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Xilio Therapeutics has a beta of -0.16, meaning that its stock price is 116% less volatile than the broader market. Comparatively, Hoth Therapeutics has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market.

Hoth Therapeutics has lower revenue, but higher earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Hoth Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.13	-$35.04M	-$3.55	N/A
Hoth Therapeutics	N/A	N/A	-$12.47M	-$0.80	N/A

In the previous week, Hoth Therapeutics had 2 more articles in the media than Xilio Therapeutics. MarketBeat recorded 3 mentions for Hoth Therapeutics and 1 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 0.50 beat Hoth Therapeutics' score of -0.32 indicating that Xilio Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xilio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hoth Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hoth Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Xilio Therapeutics' return on equity of -151.42% beat Hoth Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-58.52%	-151.42%	-27.61%
Hoth Therapeutics	N/A	-165.25%	-143.61%

Summary

Xilio Therapeutics beats Hoth Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Hoth Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HOTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HOTH vs. The Competition

Export

Metric	Hoth Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.24M	$3.38B	$6.40B	$12.31B
Dividend Yield	N/A	2.27%	2.76%	5.30%
P/E Ratio	-0.86	10.53	17.90	22.89
Price / Sales	N/A	323.05	553.40	86.95
Price / Cash	N/A	131.89	44.57	56.72
Price / Book	3.14	7.11	10.35	7.12
Net Income	-$12.47M	$24.45M	$3.56B	$335.28M
7 Day Performance	9.00%	3.35%	4.91%	2.66%
1 Month Performance	-13.54%	-0.67%	1.51%	1.39%
1 Year Performance	-17.82%	61.97%	36.04%	35.43%

Hoth Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HOTH Hoth Therapeutics	2.4162 of 5 stars	$0.69 +7.8%	$5.00 +624.6%	-23.4%	$12.24M	N/A	N/A	4	Earnings Report
OKUR OnKure Therapeutics	2.7732 of 5 stars	$3.42 -0.6%	$27.00 +689.5%	+80.9%	$46.68M	N/A	N/A	N/A
ZYBT Zhengye Biotechnology	N/A	$0.99 -1.2%	N/A	-90.2%	$46.68M	$16.64M	N/A	278	Gap Down
ELUT Elutia	1.9248 of 5 stars	$1.10 +3.6%	$6.00 +446.4%	-31.0%	$46.63M	$12.29M	1.33	180
IXHL Incannex Healthcare	1.1994 of 5 stars	$3.90 -14.0%	N/A	-46.3%	$46.47M	$90K	N/A	3	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HOTH) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hoth Therapeutics (HOTH) Competitors

HOTH vs. OKUR, ZYBT, ELUT, IXHL, and XLO

How does Hoth Therapeutics compare to OnKure Therapeutics?

Summary

How does Hoth Therapeutics compare to Zhengye Biotechnology?

Summary

How does Hoth Therapeutics compare to Elutia?

Summary

How does Hoth Therapeutics compare to Incannex Healthcare?

Summary

How does Hoth Therapeutics compare to Xilio Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOTH vs. The Competition

Hoth Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hoth Therapeutics (HOTH) Competitors

HOTH vs. OKUR, ZYBT, ELUT, IXHL, and XLO

How does Hoth Therapeutics compare to OnKure Therapeutics?

Which has more volatility and risk, OKUR or HOTH?

Is OKUR or HOTH more profitable?

Does the media favor OKUR or HOTH?

Do institutionals and insiders believe in OKUR or HOTH?

Which has higher valuation and earnings, OKUR or HOTH?

Do analysts rate OKUR or HOTH?

Summary

How does Hoth Therapeutics compare to Zhengye Biotechnology?

Which has more risk and volatility, HOTH or ZYBT?

Is HOTH or ZYBT more profitable?

Does the media prefer HOTH or ZYBT?

Do analysts recommend HOTH or ZYBT?

Which has higher earnings & valuation, HOTH or ZYBT?

Do insiders & institutionals hold more shares of HOTH or ZYBT?

Summary

How does Hoth Therapeutics compare to Elutia?

Do insiders and institutionals hold more shares of ELUT or HOTH?

Is ELUT or HOTH more profitable?

Does the media prefer ELUT or HOTH?

Which has more risk & volatility, ELUT or HOTH?

Do analysts recommend ELUT or HOTH?

Which has preferable valuation & earnings, ELUT or HOTH?

Summary

How does Hoth Therapeutics compare to Incannex Healthcare?

Do institutionals & insiders believe in HOTH or IXHL?

Which has more volatility and risk, HOTH or IXHL?

Does the media prefer HOTH or IXHL?

Is HOTH or IXHL more profitable?

Which has preferable earnings and valuation, HOTH or IXHL?

Do analysts rate HOTH or IXHL?

Summary

How does Hoth Therapeutics compare to Xilio Therapeutics?

Do insiders & institutionals have more ownership in XLO or HOTH?

Do analysts rate XLO or HOTH?

Which has more risk & volatility, XLO or HOTH?

Which has higher valuation and earnings, XLO or HOTH?

Does the media favor XLO or HOTH?

Is XLO or HOTH more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOTH vs. The Competition

Hoth Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools